Immune Therapeutics Stock Beta
IMUNDelisted Stock | USD 0.06 0 4.76% |
Immune Therapeutics fundamentals help investors to digest information that contributes to Immune Therapeutics' financial success or failures. It also enables traders to predict the movement of Immune Pink Sheet. The fundamental analysis module provides a way to measure Immune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Therapeutics pink sheet.
Immune |
Immune Therapeutics Company Beta Analysis
Immune Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Immune Therapeutics Beta | 0.52 |
Most of Immune Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Immune Therapeutics has a Beta of 0.5171. This is 39.87% lower than that of the Biotechnology sector and 62.8% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Immune Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Immune Therapeutics could also be used in its relative valuation, which is a method of valuing Immune Therapeutics by comparing valuation metrics of similar companies.Immune Therapeutics is currently under evaluation in beta category among related companies.
As returns on the market increase, Immune Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Immune Therapeutics is expected to be smaller as well.
Immune Fundamentals
Return On Asset | -0.45 | |||
Current Valuation | 83.25 M | |||
Shares Outstanding | 82.76 M | |||
Shares Owned By Insiders | 29.51 % | |||
Price To Earning | 333.33 X | |||
Price To Sales | 161.50 X | |||
Gross Profit | 65.83 K | |||
EBITDA | 3.8 M | |||
Net Income | 3.59 M | |||
Cash And Equivalents | 271.53 K | |||
Total Debt | 1.08 M | |||
Debt To Equity | 1.97 % | |||
Current Ratio | 0.04 X | |||
Book Value Per Share | (0.03) X | |||
Cash Flow From Operations | (231.72 K) | |||
Earnings Per Share | 0.03 X | |||
Number Of Employees | 15 | |||
Beta | 0.52 | |||
Market Capitalization | 39.1 M | |||
Total Asset | 3.14 M | |||
Retained Earnings | (319.86 M) | |||
Working Capital | (7.47 M) | |||
Current Asset | 22 K | |||
Current Liabilities | 7.49 M | |||
Net Asset | 3.14 M |
About Immune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immune Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immune Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Therapeutics' short interest history, or implied volatility extrapolated from Immune Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |